Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
---|
07/10/2003 | US20030129242 Sterile filtered nanoparticulate formulations of budesonide and beclomethasone having tyloxapol as a surface stabilizer |
07/10/2003 | US20030129241 Effective amount of a vasoactive prostaglandin, a polysaccharide thickener, a lipophilic component, and an acidic buffer system |
07/10/2003 | US20030129240 Polyoxyalkylene block copolymer at desired concentrations with or without a therapeutic agent |
07/10/2003 | US20030129239 Water soluble nanoparticles of hydrophilic and hydrophobic active materials and an apparatus and method for their production |
07/10/2003 | US20030129238 Edible, hardenable, prompt release coating of microcrystalline cellulose (mcc), a film forming propylene glycol alginate (pga), a strengthening polymer and a plasticizer, a surface active agent and a filler |
07/10/2003 | US20030129237 Multiparticulate modified release composition |
07/10/2003 | US20030129236 Clindamycin released in a first pulse, within thirty minutes of administration, and a second pulse 4-15 hours after |
07/10/2003 | US20030129235 Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor |
07/10/2003 | US20030129234 Methods of making sustained release formulations of oxymorphone |
07/10/2003 | US20030129233 Sustained release hydrophobic bioactive PLGA microspheres |
07/10/2003 | US20030129232 Biologically absorbable polyhydroxycarboxylic acid and production method thereof |
07/10/2003 | US20030129231 Carrier causes oxycodone hydrochloride to preferentially release the drug in gastric fluid; analgesics |
07/10/2003 | US20030129230 Sustained release formulations of oxymorphone |
07/10/2003 | US20030129229 Pulse dosage formulations of methylphenidate and method to prepare same |
07/10/2003 | US20030129228 Magnesium plus interactive agent delivery |
07/10/2003 | US20030129227 Beta-lactam antibiotic-containing tablet and production thereof |
07/10/2003 | US20030129226 Water soluble polymer-based rapidly dissolving tablets and production processes thereof |
07/10/2003 | US20030129225 Topical formulations of natamycin/pimaricin |
07/10/2003 | US20030129224 Liposomes containing a vesicle forming lipid and an aggreagation preventing component free of cholesterol, and the liposomes contain an encapsulated anticancer drug; osmolarity of intraliposomal aqueous medium =< 500 mOsm/kg less |
07/10/2003 | US20030129222 Administering to a cancer patient a therapeutically effective amount of imexon or derivative in combination with one or more lipids to treat the cancer |
07/10/2003 | US20030129221 A mixture of lipids containing a protonatable or deprotonatable lipid, such as polyoxyethylene glycol or polyamide oligomer modified lipid, or amino lipid is combined with a buffered aqueous solution of a charged drug |
07/10/2003 | US20030129220 Transdermal administration of androgenic drugs using hydroxide-releasing agents as permeation enhancers |
07/10/2003 | US20030129219 Self-emulsifying matrix type trandermal preparation |
07/10/2003 | US20030129211 Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides |
07/10/2003 | US20030129209 Topical application of cetirizine and loratadine |
07/10/2003 | US20030129182 Contacting vitreous humor with beta-glucuronidase, matrix metalloproteinase, chondroitinase, chondroitin sulfatase, and/or protein kinase; thimerosal-free |
07/10/2003 | US20030129172 Animal growth regulator |
07/10/2003 | US20030129156 Use of a polypeptide for treatment of pruritis in animals |
07/10/2003 | US20030129145 Aftersmoking; converting nicotine to cotinine; discharing in urine |
07/10/2003 | US20030129141 Dispersable dry powder; controlling moisture concentration, particle size; in situ drug delivery |
07/10/2003 | US20030129140 In situ infection therapy; aminoglycoside antibiotics |
07/10/2003 | US20030129139 Drug delivery; lightweight hollow spheres; spray drying |
07/10/2003 | US20030129137 Stable microbubble suspensions as enhancement agents for ultrasound echography |
07/10/2003 | US20030129130 Drug delivery; microparticles immobilized on polymer surface |
07/10/2003 | US20030127760 Apparatus and methods for forming patterned soft gelatin capsules |
07/10/2003 | US20030127207 Antimicrobially-treated fabrics |
07/10/2003 | CA2511902A1 Seal oil based lipid emulsions and uses thereof |
07/10/2003 | CA2472401A1 Improved method of production of lycopene by the fermentation of selected strains of blakeslea trispora, formulations and uses of the lycopene obtained |
07/10/2003 | CA2471903A1 Micronized pharmaceutical or nutraceutical powder with immediate release |
07/10/2003 | CA2471798A1 Adhesive transdermal formulations of diclofenac sodium |
07/10/2003 | CA2471300A1 Composition comprising dextrinsulfate for the treatment of sexual transmitted diseases (std) |
07/10/2003 | CA2471039A1 Method of systemically delivering ssris |
07/10/2003 | CA2470684A1 A haemostatic kit, a method of preparing a haemostatic agent and a method of promoting haemostatis |
07/10/2003 | CA2470545A1 Heteroxylan film-forming composition for making capsules and resulting capsules |
07/10/2003 | CA2470511A1 Liquid composition of factor vii polypeptides |
07/10/2003 | CA2469214A1 Improved polymer-lipid delivery vehicles |
07/10/2003 | CA2468081A1 Conjugates comprising an antibody specific for the ed-b domain of fibronectin and their use for the detection and treatment of tumours |
07/10/2003 | CA2463738A1 Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi) |
07/10/2003 | CA2416030A1 Sedative non-benzodiazepine formulations |
07/09/2003 | EP1325765A1 Combinations of Formoterol and Mometasone Furoate for Asthma |
07/09/2003 | EP1325757A1 Embolic materials |
07/09/2003 | EP1325753A2 Bio-compatible means for controlled drug delivery to tissue and method of use |
07/09/2003 | EP1325752A2 Composition for transdermal and/or transmucosal administration of active compounds which ensures adequate therapeutic levels |
07/09/2003 | EP1325746A1 Controlled release oxycodone compositions |
07/09/2003 | EP1325742A1 Improved transdermal therapeutic system for the treatment of Parkinson's disease |
07/09/2003 | EP1325741A2 Implantable delivery device with self adjustable exit port |
07/09/2003 | EP1325740A1 Stable granulates containing S-Adenosylmethionine and process for the preparation thereof |
07/09/2003 | EP1325739A1 Liposomes encapsulating anticancer drugs and the use thereof in the treatment of malignant tumors |
07/09/2003 | EP1325116A2 Isoprenoid-dependent ras anchorage (idra) proteins |
07/09/2003 | EP1325046A1 Zwitterionic polymers |
07/09/2003 | EP1325044A1 Aqueous polymer dispersion |
07/09/2003 | EP1325035A1 Starch |
07/09/2003 | EP1325034A1 Pharmaceutically acceptable starch |
07/09/2003 | EP1324972A1 Dihydroxy open-acid salt of simvastatin |
07/09/2003 | EP1324797A2 Medicament dispenser |
07/09/2003 | EP1324789A2 Fluid material dispensing syringe |
07/09/2003 | EP1324782A2 Stabilized hydrogen peroxide solutions |
07/09/2003 | EP1324776A2 Reduced-viscosity concentrated protein formulations |
07/09/2003 | EP1324769A2 Split enveloped virus preparation for intranasal delivery |
07/09/2003 | EP1324760A1 Creatine ester pronutrient compounds and formulations |
07/09/2003 | EP1324758A1 Method for preparing microspheres containing a water-soluble substance |
07/09/2003 | EP1324755A1 Pharmaceutical solutions of modafinil compounds |
07/09/2003 | EP1324753A2 Compositions and methods for lowering plasma lipoprotein(a) and risk factors of cardiovascular diseases |
07/09/2003 | EP1324752A2 Delayed release pharmaceutical formulations |
07/09/2003 | EP1324750A1 Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment |
07/09/2003 | EP1324749A2 Medicinal aerosol formulations |
07/09/2003 | EP1324748A1 Topical antibiotic composition for treatment of eye infection |
07/09/2003 | EP1231896A4 Taste masked oral compositions |
07/09/2003 | EP1175210A4 Increasing cerebral bioavailability of drugs |
07/09/2003 | EP1173151B1 Dry, mouldable drug formulation |
07/09/2003 | EP1165051B1 Process for the preparation of a bioavailable oral dosage form of cefuroxime axetil |
07/09/2003 | EP1143929B1 BIODEGRADABLE pH/THERMOSENSITIVE HYDROGELS FOR SUSTAINED DELIVERY OF BIOLOGICALLY ACTIVE AGENTS |
07/09/2003 | EP1035862B1 Cyclosporin-containing microemulsion preconcentrate composition |
07/09/2003 | EP1031345B1 Gel preparation containing polystyrene-sulfonates |
07/09/2003 | EP1028706B1 Buffered drug formulations for transdermal electrotransport delivery |
07/09/2003 | EP1009385B1 Cholesterol level lowering composition |
07/09/2003 | EP1007015B1 In situ formation of polymeric material |
07/09/2003 | EP0994703B1 Composition comprising ketanserin and l-carnitine for the treatment of crps |
07/09/2003 | EP0975326B1 Topical application of enzymes using a peelable film |
07/09/2003 | EP0964690B1 Peptide-lipid conjugates, liposomes and liposomal drug delivery |
07/09/2003 | EP0790823B1 Drug releasing surgical implant or dressing material |
07/09/2003 | EP0619738B1 Inhibitory immunoglobulin polypeptides to human pdgf beta receptor |
07/09/2003 | EP0612242B1 Use of the pure s(+) isomer of fluoxetine for the preparation of a medicament against migraine headache |
07/09/2003 | EP0573576B2 Compositions for topical administration of pharmaceutically active agents |
07/09/2003 | EP0190315B2 Dehydrated liposomes |
07/09/2003 | CN1429220A Crystalline base of citalopram |
07/09/2003 | CN1429205A 磺酰胺衍生物 Sulfonamide derivatives |
07/09/2003 | CN1429120A Stable polymeric micelle-type drug composition and method for preparation thereof |
07/09/2003 | CN1429119A Method for preparation of polymeric micelle via separation of block copolymer |
07/09/2003 | CN1429116A Pharmaceutical composition |